clinical trial · NCT05362487
Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug
Boehringer Ingelheim·—·terminated·n = 9
Pulmonary Disease, Chronic ObstructiveSpiriva® Respimat®Spiriva® HandiHaler®Tiotropium bromide
brief summary
The objective of this non-interventional, observational study is to assess whether changing Chronic Obstructive Pulmonary Disease (COPD) patients from a dry powder inhaler (HandiHaler®) to a soft mist inhaler (Respimat®), without changing the pharmacological compound, will lead to an improvement in Clinical COPD Questionnaire (CCQ) score and in the scores of the three subdomains of CCQ score: symptoms (4 items), functional state (4 items) and mental state (2 items) during a study period of approximately 8 weeks.
started
Aug 5, 2022
primary completion
Jan 18, 2023
completion
Jan 18, 2023
last updated
Feb 26, 2025
official title
Switching COPD Patients From Spiriva® HandiHaler® Maintenance Therapy to Spiriva® Respimat®: a Non-Interventional Real-world clinicAl ouTcome assEssment: NIS PIRATE
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol